Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BMS’s Bladder Cancer Program Sees Change In Fortunes With Opdivo Substudy Win

Jul 11 2023

• By Alaric DeArment

Bristol Myers Squibb announced topline results from a substudy of the CheckMate-901 trial • Source: Shutterstock

Related Content

Merck KGaA Could Benefit From Bavencio Sales Growth Until 2024

May 11 2023

Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs

Mar 13 2023

Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames

Apr 15 2022

Bristol’s Opdivo Stumbles On Its Way To First-Line Bladder Cancer Indication

May 16 2022

Related Companies

Bristol Myers Squibb Company

Nektar Therapeutics

Merck & Co., Inc.

Seagen Inc.

Pfizer Inc.

Merck KGaA

Additional Topics

Clinical Trials ImmunoOncology Research & Development BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window